Barkan A, Barkan E, Hoogervorst-Spalter H, Kaufman H, Klein A
J Natl Cancer Inst. 1980 Jun;64(6):1333-5. doi: 10.1093/jnci/64.6.1333.
Because lymphocytic cortisol metabolism-enhancing factor (LCMEF) is absent in the plasma of cancer patients (CP), this study was undertaken to determine the influence of tumor removal on this phenomenon. Known concentrations of human lymphocytes were incubated with cortisol in media containing 50% phosphate-buffered saline (PBS) and 50% of one of the following: a) homologic normal plasma (HP),b) plasma from patients with noncancerous diseases (NCD) before surgery, c) plasma from patients with NCD after surgery, d) plasma from CP before tumor removal, e) plasma from CP after tumor removal, f) plasma from long-surviving CP (LSCP), and g) PBS. With the exception of plasma from the LSCP group, all the plasma had the capacity to enhance the lymphocytic cortisol metabolism (LCM) when compared with that of PBS. There was no significant difference between the metabolism obtained with HP and that obtained with plasma from patients with NCD either before or after surgery. The plasma from CP led to a significant reduction in activity, with no significant difference in conversion rates before and after tumor removal. The plasma from LSCP failed to enhance LCM, had a conversion rate similar to that of PBS and significantly lower than that of the plasma from CP, and appeared to contain no LCMEF. These findings, which showed that the lack of LCMEF in CP is not influenced by tumor removal, may indicate 1) that the lack of LCMEF preceded the appearance of cancer or 2) irreversibility of a possible anti-LCMEF synthesis effect was induced by the tumor.
由于癌症患者（CP）血浆中不存在淋巴细胞皮质醇代谢增强因子（LCMEF），因此开展本研究以确定肿瘤切除对此现象的影响。将已知浓度的人淋巴细胞与皮质醇在含有50%磷酸盐缓冲盐水（PBS）和以下之一的50%的培养基中孵育：a）同种正常血浆（HP），b）非癌性疾病（NCD）患者术前血浆，c）NCD患者术后血浆，d）肿瘤切除前CP患者血浆，e）肿瘤切除后CP患者血浆，f）长期存活的CP患者（LSCP）血浆，以及g）PBS。除LSCP组血浆外，与PBS相比，所有血浆均具有增强淋巴细胞皮质醇代谢（LCM）的能力。HP获得的代谢与NCD患者术前或术后血浆获得的代谢之间无显著差异。CP患者的血浆导致活性显著降低，肿瘤切除前后转化率无显著差异。LSCP患者的血浆未能增强LCM，其转化率与PBS相似，且显著低于CP患者的血浆，并且似乎不含LCMEF。这些结果表明CP中LCMEF的缺乏不受肿瘤切除的影响，这可能表明1）LCMEF的缺乏先于癌症出现，或者2）肿瘤诱导了可能的抗LCMEF合成效应的不可逆性。
